Company: SMNR
Filing Date: 2025-07-02
Form Type: S-4/A
Source: 0001193125-25-154936
Chunk: 588

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-02
Form: S-4/A
Chunk 588
---
uming No            
 Redemptions)            |          |   |     | Pro Forma     
 Combined      
 (Assuming 25% 
 Redemption)   |          |   |     | Pro Forma     
 Combined      
 (Assuming 50% 
 Redemption)   |          |   |     | Pro Forma     
 Combined      
 (Assuming 75% 
 Redemption)   |          |   |     | Pro Forma      
 Combined       
 (Assuming 100% 
 Redemption)    |          |   |
| Pro forma net loss (in thousands)                                         |     | $                       | (365,878 | ) |     | $             | (365,878 | ) |     | $             | (365,878 | ) |     | $             | (365,878 | ) |     | $              | (365,878 | ) |
| Weighted average shares outstanding – basic and diluted (thousands)(1)(2) |     |                         |  211,626 |   |     |               |  211,615 |   |     |               |  211,604 |   |     |               |  211,593 |   |     |                |  211,582 |   |
| Net loss per share – basic and diluted                                    |     | $                       |    (1.73 | ) |     | $             |    (1.73 | ) |     | $             |    (1.73 | ) |     | $             |    (1.73 | ) |     | $              |    (1.73 | ) |

| (1) | The no redemption scenario is comprised of 211,626,025 weighted average of shares of New Semnur Common Stock outstanding. The 25% redemption scenario is comprised of 211,615,090 weighted average shares of New Semnur Common Stock outstanding. The 50% redemption scenario is comprised of 211,604,155 weighted average shares of New Semnur Common Stock outstanding. The 75% redemption scenario is comprised of 211,593,220 weighted average of shares of New Semnur Common Stock outstanding. The 100% redemption scenario is comprised of 211,582,286 weighted average shares of New Semnur Common Stock outstanding. |

All scenarios under the diluted Earnings Per Share (“EPS”) calculation exclude the potential dilutive effect of the following securities because it is unknown whether such securities will ever be exercised for shares